Skip to content
lifestyle.gamezon.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NanoViricides
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
July 6, 2026
US FDA Has Granted A “Rare Pediatric Disease Drug” Designation for NV-387 As A Treatment for Measles – Enables Priority Review Voucher
June 29, 2026
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
June 22, 2026
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola – NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
June 15, 2026
Ebola Global Health Emergency Needs a Broad-Spectrum Drug – NV-387 is a Strong Potential Candidate, Says NanoViricides
May 18, 2026
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
February 12, 2026
←
Previous Page
1
2
3